The role of VEGF-C in resisting stress in prostate cancer
VEGF-C在前列腺癌抗应激中的作用
基本信息
- 批准号:8458896
- 负责人:
- 金额:$ 28.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-02-01 至 2015-01-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAddressAndrogensAnimal ModelApoptosisCancer EtiologyCancer PatientCellular StressCessation of lifeClinical ResearchComplexCutaneousDevelopmentDiseaseFailureFrequenciesGoalsHormonalHumanHypoxiaImmunocompromised HostIn VitroIonizing radiationKnockout MiceLymphangiogenesisLymphatic vesselMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of prostateMediatingMetastatic Prostate CancerModelingMolecularMusNKX3-1 geneNeoplasm MetastasisNeuropilin-2OutcomeOxidative StressPTEN genePathway interactionsPatientsProcessPrognostic MarkerProstatectomyProto-Oncogene Proteins c-aktPublicationsRadiationRadiation therapyRecurrenceRefractoryResistanceRoleSpecimenStagingStreamStressTherapeutic InterventionTissuesTransgenic MiceTransgenic OrganismsVascular Endothelial Growth Factor CWestern Worldabstractingcancer cellcancer recurrencecohortdeprivationeffective therapyhuman FRAP1 proteinimplantationlymph nodesmeetingsmenmortalitymouse modelnew growthnovelparacrineprognosticprostate cancer cellreceptortherapeutic targettherapy resistanttissue culturetumor
项目摘要
Project summary/Abstract
Prostate cancer remains the most common non- cutaneous malignancy in the Western world and is the
second highest cause of cancer death in men after lung cancer. The main reason for prostate cancer mortality is
the failure to cure patients with metastatic disease. A number of publications have demonstrated an increase in
expression of vascular endothelial growth factor-C (VEGF-C) in metastatic prostate cancer when compared to
primary prostate cancer. Our preliminary results suggest a direct role of VEGF-C in promoting survival of
prostate cancer cells during stress. This function of VEGF-C is distinctly different from its known paracrine
function of inducing the growth of new lymphatic vessels. We believe that by protecting the prostate cancer
cells from stress-induced apoptosis, VEGF-C promotes prostate cancer recurrence and metastasis. Interestingly,
in many recent clinical studies, VEGF-C expression is correlated with cancer recurrence, further supporting our
findings. We hypothesize that the survival promoting function of VEGF-C during stress is necessary for the
development of therapy-resistant and metastatic prostate cancer. The goal of this proposal is to understand the
importance of VEGF-C as a prognostic as well as a therapeutic target for refractory, metastatic prostate cancer.
Three specific aims will address this goal. In Aim 1, we will elucidate the molecular mechanism of VEGF-C
mediated stress resistance of prostate cancer cells. We will determine the involvement of VEGF-C receptor,
neuropilin-2 in regulating the mTOR complex-2/AKT-1 pathway in prostate cancer cells under oxidative stress.
Our study will therefore provide information about the upstream mechanisms of mTOR complex-2 activation. We
will also determine the role of VEGF-C in resisting hypoxic stress in prostate cancer especially after androgen
ablation. In aim 2, we will investigate the role of VEGF-C in therapy resistant prostate cancer cells. The stress-
resistant function of the VEGF-C/Neuropilin-2/m-TORC-2/AKT-1 axis in prostate cancer cells will be evaluated
following ionizing radiation alone or in combination with androgen deprivation. Both in vitro tissue culture models
and animal models of prostate cancer (Orthotopic implantation of VEGF-C expressing human prostate cancer
cells in immunocompromised mice and transgenic NKX3.1;PTEN knock-out mice) will be used. In aim 3, we will
compare the tissue expression levels of VEGF-C and their down-stream targets with the frequency of recurrence
of human prostate cancer following prostatectomy. The association of high VEGF-C expression levels with
cancer recurrence following prostatectomy will be determined in a cohort of approximately three hundred patients
with locally invasive prostate cancer and prostate cancer with metastases in the regional lymph nodes. The role
of downstream targets of VEGF-C (e.g. Phospho-AKT-1 (Ser 473), neuropilin-2, phospho c-Met, phospho-
FOXO-1 and phospho-mTOR) in promoting survival will also be evaluated. This study should provide potential
targets for effective therapeutic interventions as well as prognostic indicators for the metastatic stage of prostate
cancer.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kaustubh Datta其他文献
Kaustubh Datta的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kaustubh Datta', 18)}}的其他基金
Nuclear Neuropilin2: a novel molecular mediator for aggressive Prostate Cancer
Nuclear Neuropilin2:一种治疗侵袭性前列腺癌的新型分子介质
- 批准号:
10607992 - 财政年份:2020
- 资助金额:
$ 28.1万 - 项目类别:
Nuclear Neuropilin2: a novel molecular mediator for aggressive Prostate Cancer
Nuclear Neuropilin2:一种治疗侵袭性前列腺癌的新型分子介质
- 批准号:
10112850 - 财政年份:2020
- 资助金额:
$ 28.1万 - 项目类别:
Nuclear Neuropilin2: a novel molecular mediator for aggressive Prostate Cancer
Nuclear Neuropilin2:一种治疗侵袭性前列腺癌的新型分子介质
- 批准号:
9888104 - 财政年份:2020
- 资助金额:
$ 28.1万 - 项目类别:
Nuclear Neuropilin2: a novel molecular mediator for aggressive Prostate Cancer
Nuclear Neuropilin2:一种治疗侵袭性前列腺癌的新型分子介质
- 批准号:
10375361 - 财政年份:2020
- 资助金额:
$ 28.1万 - 项目类别:
Neuropilin-2 Axis in Docetaxel Resistance and Prostate Cancer Bone Metastasis
Neuropilin-2 轴在多西紫杉醇耐药和前列腺癌骨转移中的作用
- 批准号:
9220727 - 财政年份:2015
- 资助金额:
$ 28.1万 - 项目类别:
The role of VEGF-C in resisting stress in prostate cancer
VEGF-C在前列腺癌抗应激中的作用
- 批准号:
8606427 - 财政年份:2010
- 资助金额:
$ 28.1万 - 项目类别:
The role of VEGF-C in resisting stress in prostate cancer
VEGF-C在前列腺癌抗应激中的作用
- 批准号:
7899319 - 财政年份:2010
- 资助金额:
$ 28.1万 - 项目类别:
The role of VEGF-C in resisting stress in prostate cancer
VEGF-C在前列腺癌抗应激中的作用
- 批准号:
8321658 - 财政年份:2010
- 资助金额:
$ 28.1万 - 项目类别:
The role of VEGF-C in resisting stress in prostate cancer
VEGF-C在前列腺癌抗应激中的作用
- 批准号:
8018658 - 财政年份:2010
- 资助金额:
$ 28.1万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 28.1万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 28.1万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 28.1万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 28.1万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 28.1万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 28.1万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 28.1万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 28.1万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 28.1万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 28.1万 - 项目类别:
Research Grant














{{item.name}}会员




